KIMMTRAK is a pioneering TCR bispecific therapy that targets the gp100 antigen in patients with HLA-A*02:01-positive unresectable or metastatic uveal melanoma. It works by re-directing T cells to recognize and destroy tumor cells, providing a significant survival benefit for a previously difficult-to-treat cancer.
Pain Points: Lack of effective treatment options for uveal melanoma; tumor cells hiding from the immune system.
Solutions: Directs the immune system to recognize and destroy cancer cells specifically expressing the targeted antigen.
Target Users: HLA-A*02:01-positive patients suffering from metastatic or unresectable uveal melanoma.
Supply Chain
In-house research and clinical developmentContract manufacturing organizations (CMOs) for biologic productionClinical research organizations (CROs) for clinical trial executionGlobal oncology distribution networks
Brenetafusp is currently in development targeting the PRAME antigen across several solid tumor indications, including advanced cutaneous melanoma, ovarian cancer, and non-small cell lung cancer (NSCLC).
Price Range: N/A (In clinical trials)
Pain Points: Limited efficacy of traditional therapies in late-stage solid tumors.
Solutions: Harnesses T cell immunity against PRAME-expressing solid tumor cells.
